title: Evolving treatments in multiple myeloma patients with renal failure.
abstract: The introduction of novel agents in multiple myeloma therapy has dramatically improved survival in latest years. Great progress has also been detected in particular poor clinical situation such as acute renal failure in which survival was dismal in the past. Treatment with bortezomib, thalidomide and dialysis associated with high cut-off (HCO) filters can recover more than two thirds of myeloma patients with an end stage renal failure. Novel proteasome inhibitors and immunomodulating agents (IMID's) are even more promising in this set of patients. Aim of this review is to provide an overview of treatments of multiple myeloma patients with acute renal failure coming from most recent clinical trials.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gozzetti
authors.forename: Giulia
authors.initials: G
authors.lastname: Papini
authors.forename: Veronica
authors.initials: V
authors.lastname: Candi
authors.affiliation: Hematology, Policlinico "Santa Maria alle Scotte", Viale Bracci 16, 53100 Siena, Italy. gozzetti@unisi.it.
authors.forename: Monica
authors.initials: M
authors.lastname: Bocchia
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy*; D009101:Multiple Myeloma / Q000150:complications / Q000628:therapy*; D006435:Renal Dialysis / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents